Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Leukemia

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States

Leuk Lymphoma

Toreli ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, Miranda E, Fechio L, Silva Santos Duarte A, Basso A, Duarte G, Souza Medina S, Pericole F, Benites B, Jones K, Singh H, Farmaha J, Vashisht A, Kolhe R, Mondal AK, Saad STO, de Souza CA, Cortes JE, Pagnano K

doi: 10.1080/10428194.2024.2367057

Leukemia

Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland

Br J Haematol

Vedi A, Leiter SM, Memon IL, Mahendrayogam A, Van Rijswijk E, Uparkar U, Shenton G, Trinquand A, Clesham K, McLelland V, Campbell H, Patrick K, Thompson L, Baird S, Connor P, Lancaster D, James B

doi: 10.1111/bjh.19843

Leukemia

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

Haematologica

Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG

doi: 10.3324/haematol.2023.284860

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

Leukemia

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Leuk Lymphoma

Abé C, Keto J, Lilja M, Konradsen M, Mesterton J, Höglund M, Lazarevic V, Lehmann S, Juliusson G

doi: 10.1080/10428194.2024.2363430

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Further Publications

Real-world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies

Br J Haematol

Wilson A, Moussa A, Trinquand A, Malone A, Tewari S, Calvert R, Patrick K, Nicholson E, Smith K, Grandage V, Baird S, George L, Qureshi A, Borg A, Gibson B, Patel P, Bartram J, Samrin L, O'Connor D

doi: 10.1111/bjh.19791

Related content

Results of TRODELVY® real-world data

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States

Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Real-world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies

Results of TRODELVY^® real-world data

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement